Quantcast
Home > Quotes > INSM
INSM

Insmed, Inc. Common Stock (INSM) Quote & Summary Data

$25.24
*  
0.10
0.39%
Get INSM Alerts
*Delayed - data as of Jul. 16, 2018  -  Find a broker to begin trading INSM now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
39.5
Today's High / Low
$ 25.55 / $ 24.81
Share Volume
433,195
50 Day Avg. Daily Volume
612,026
Previous Close
$ 25.34
52 Week High / Low
$ 33.94 / $ 11.49
Market Cap
1,933,967,953
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -3.15
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.26

Intraday Chart

Shares Traded

Share Volume:
433,195
50 Day Avg. Daily Volume:
612,026

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.15

Trading Range

The current last sale of $25.24 is 119.67% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 25.55 $ 33.94
 Low: $ 24.81 $ 11.49

Company Description (as filed with the SEC)

Insmed is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. Our lead product candidate is amikacin liposome inhalation suspension (ALIS) (formerly known as liposomal amikacin for inhalation), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC), a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Our earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is a novel oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), an enzyme responsible for activating neutrophil serine proteases, which are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis (non-CF) bronchiectasis.  ... More ...  

Risk Grade

Where does INSM fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 25.32
Open Date:
Jul. 16, 2018
Close Price:
$ 25.24
Close Date:
Jul. 16, 2018

Consensus Recommendation

Analyst Info